Reliable biomarkers to predict ICI response in STS are understudied and currently lacking.<h4>Methods</h4>We examined mutation profiles and analysed longitudinal blood samples from STS patients (n=13) treated with anti-PD-1/PD-L1-based therapy to identify molecular features and circulating immune correlates of ICI efficacy. This evidence concerns the gene PDCD1 and telomere syndrome.